Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses
Identifieur interne : 002222 ( Main/Exploration ); précédent : 002221; suivant : 002223Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses
Auteurs : Brian R. Murphy [États-Unis] ; Gregory A. Prince [États-Unis] ; Peter L. Collins [États-Unis] ; Kathleen Van Wyke Coelingh [États-Unis] ; Robert A. Olmsted [États-Unis] ; Melanie K. Spriggs [États-Unis] ; Robert H. Parrott [États-Unis] ; Hyun-Wha Kim [États-Unis] ; Carl D. Brandt [États-Unis] ; Robert M. Chanock [États-Unis]Source :
- Virus Research [ 0168-1702 ] ; 1988.
English descriptors
- Teeft :
- Amino acid sequence, Antibody response, Antigenic, Antigenic characterization, Antigenic relatedness, Antigenically, Attenuated, Bovine, Cell line, Chanock, Cleavage site, Coelingh, Complete protection, Cotton rats, Fusion protein, Glycoprotein, Greater degree, Hamster, High level, Human disease, Human parainfluenza virus type, Immunization, Immunogenicity, Infectious diseases, Mcintosh, Measles, Measles virus, Monoclonal antibodies, Mutant, Neutralizing, Neutralizing antibodies, Nucleotide sequence, Olmsted, Parainfluenza, Parainfluenza virus type, Parainfluenza viruses, Parrott, Patas monkeys, Primates, Protease, Recombinant, Recombinant vaccinia viruses, Replication, Respiratory syncytial virus, Respiratory syncytial virus infection, Respiratory tract disease, Rhesus, Sendai virus, Serially passaged, Serious disease, Serum neutralizing antibodies, Spriggs, Stott, Subgroup, Subunit, Subunit vaccine, Subunit vaccines, Surface glycoproteins, Syncytial, Syncytial virus, Vaccine, Vaccinia, Vaccinia virus, Vaccinia viruses, Virol, Virology, Virus, Virus vaccine, Wertz, Wild type virus.
Abstract
Abstract: Vaccines against parainfluenza (PIV) and respiratory syncytial viruses (RSV) that are currently being developed include both live and subunit vaccines. Candidate live PIV vaccines that have been found to be attenuated and efficacious in rodents or primate models are (1) cold-adapted, temperature-sensitive mutants of PIV-type 3 that have been serially passaged at low temperature (20 ° C) in simian kidney tissue culture; (2) protease-activation mutants (PIV-1-Sendai), which have mutations that decrease the cleavability of their F glycoprotein by host cell protease; (3) an animal virus, bovine PIV-3 virus, which is antigenically related to the human PIV-3 virus, and (4) vaccinia recombinant viruses bearing RSV or PIV-3 glycoproteins.Subunit RSV and PIV-3 viruses are being produced and evaluated as immunogens. A major concern with these vaccines is the possibility of disease potentiation following virus infection as occurred previously with formalin-inactivated measles and RSV vaccines. Studies indicate that PIV-3 and RSV glycoprotein vaccines are immunogenic and efficacious in animals but insufficient data exist to estimate their capacity to potentiate disease. However, since a cotton rat model is available to detect potentiated disease resulting from infection of cotton rats previously immunized with formalin-inactivated RSV vaccine, it is now possible to systematically evaluate new vaccines in experimental animals for disease potentiation before studies are initiated in humans. It is likely within the next several years that one or more of these PIV or RSV vaccines will be tested in humans for safety and immunogenicity.
Url:
DOI: 10.1016/0168-1702(88)90063-9
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001638
- to stream Istex, to step Curation: 001638
- to stream Istex, to step Checkpoint: 000F35
- to stream Main, to step Merge: 002330
- to stream Main, to step Curation: 002222
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses</title><author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R." last="Murphy">Brian R. Murphy</name></author><author><name sortKey="Prince, Gregory A" sort="Prince, Gregory A" uniqKey="Prince G" first="Gregory A." last="Prince">Gregory A. Prince</name></author><author><name sortKey="Collins, Peter L" sort="Collins, Peter L" uniqKey="Collins P" first="Peter L." last="Collins">Peter L. Collins</name></author><author><name sortKey="Van Wyke Coelingh, Kathleen" sort="Van Wyke Coelingh, Kathleen" uniqKey="Van Wyke Coelingh K" first="Kathleen" last="Van Wyke Coelingh">Kathleen Van Wyke Coelingh</name></author><author><name sortKey="Olmsted, Robert A" sort="Olmsted, Robert A" uniqKey="Olmsted R" first="Robert A." last="Olmsted">Robert A. Olmsted</name></author><author><name sortKey="Spriggs, Melanie K" sort="Spriggs, Melanie K" uniqKey="Spriggs M" first="Melanie K." last="Spriggs">Melanie K. Spriggs</name></author><author><name sortKey="Parrott, Robert H" sort="Parrott, Robert H" uniqKey="Parrott R" first="Robert H." last="Parrott">Robert H. Parrott</name></author><author><name sortKey="Kim, Hyun Wha" sort="Kim, Hyun Wha" uniqKey="Kim H" first="Hyun-Wha" last="Kim">Hyun-Wha Kim</name></author><author><name sortKey="Brandt, Carl D" sort="Brandt, Carl D" uniqKey="Brandt C" first="Carl D." last="Brandt">Carl D. Brandt</name></author><author><name sortKey="Chanock, Robert M" sort="Chanock, Robert M" uniqKey="Chanock R" first="Robert M." last="Chanock">Robert M. Chanock</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:392A2D76280235D3227C18F6E236015F8B932F02</idno><date when="1988" year="1988">1988</date><idno type="doi">10.1016/0168-1702(88)90063-9</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-9X06FSTX-Q/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001638</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001638</idno><idno type="wicri:Area/Istex/Curation">001638</idno><idno type="wicri:Area/Istex/Checkpoint">000F35</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000F35</idno><idno type="wicri:doubleKey">0168-1702:1988:Murphy B:current:approaches:to</idno><idno type="wicri:Area/Main/Merge">002330</idno><idno type="wicri:Area/Main/Curation">002222</idno><idno type="wicri:Area/Main/Exploration">002222</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses</title><author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R." last="Murphy">Brian R. Murphy</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Prince, Gregory A" sort="Prince, Gregory A" uniqKey="Prince G" first="Gregory A." last="Prince">Gregory A. Prince</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Johns Hopkins University, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Collins, Peter L" sort="Collins, Peter L" uniqKey="Collins P" first="Peter L." last="Collins">Peter L. Collins</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Van Wyke Coelingh, Kathleen" sort="Van Wyke Coelingh, Kathleen" uniqKey="Van Wyke Coelingh K" first="Kathleen" last="Van Wyke Coelingh">Kathleen Van Wyke Coelingh</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Olmsted, Robert A" sort="Olmsted, Robert A" uniqKey="Olmsted R" first="Robert A." last="Olmsted">Robert A. Olmsted</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Spriggs, Melanie K" sort="Spriggs, Melanie K" uniqKey="Spriggs M" first="Melanie K." last="Spriggs">Melanie K. Spriggs</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Parrott, Robert H" sort="Parrott, Robert H" uniqKey="Parrott R" first="Robert H." last="Parrott">Robert H. Parrott</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Children's Hospital, National Medical Center, Washington, D.C.</wicri:regionArea><wicri:noRegion>D.C.</wicri:noRegion></affiliation></author><author><name sortKey="Kim, Hyun Wha" sort="Kim, Hyun Wha" uniqKey="Kim H" first="Hyun-Wha" last="Kim">Hyun-Wha Kim</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Children's Hospital, National Medical Center, Washington, D.C.</wicri:regionArea><wicri:noRegion>D.C.</wicri:noRegion></affiliation></author><author><name sortKey="Brandt, Carl D" sort="Brandt, Carl D" uniqKey="Brandt C" first="Carl D." last="Brandt">Carl D. Brandt</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Children's Hospital, National Medical Center, Washington, D.C.</wicri:regionArea><wicri:noRegion>D.C.</wicri:noRegion></affiliation></author><author><name sortKey="Chanock, Robert M" sort="Chanock, Robert M" uniqKey="Chanock R" first="Robert M." last="Chanock">Robert M. Chanock</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Virus Research</title><title level="j" type="abbrev">VIRUS</title><idno type="ISSN">0168-1702</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1988">1988</date><biblScope unit="volume">11</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="1">1</biblScope><biblScope unit="page" to="15">15</biblScope></imprint><idno type="ISSN">0168-1702</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0168-1702</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Amino acid sequence</term><term>Antibody response</term><term>Antigenic</term><term>Antigenic characterization</term><term>Antigenic relatedness</term><term>Antigenically</term><term>Attenuated</term><term>Bovine</term><term>Cell line</term><term>Chanock</term><term>Cleavage site</term><term>Coelingh</term><term>Complete protection</term><term>Cotton rats</term><term>Fusion protein</term><term>Glycoprotein</term><term>Greater degree</term><term>Hamster</term><term>High level</term><term>Human disease</term><term>Human parainfluenza virus type</term><term>Immunization</term><term>Immunogenicity</term><term>Infectious diseases</term><term>Mcintosh</term><term>Measles</term><term>Measles virus</term><term>Monoclonal antibodies</term><term>Mutant</term><term>Neutralizing</term><term>Neutralizing antibodies</term><term>Nucleotide sequence</term><term>Olmsted</term><term>Parainfluenza</term><term>Parainfluenza virus type</term><term>Parainfluenza viruses</term><term>Parrott</term><term>Patas monkeys</term><term>Primates</term><term>Protease</term><term>Recombinant</term><term>Recombinant vaccinia viruses</term><term>Replication</term><term>Respiratory syncytial virus</term><term>Respiratory syncytial virus infection</term><term>Respiratory tract disease</term><term>Rhesus</term><term>Sendai virus</term><term>Serially passaged</term><term>Serious disease</term><term>Serum neutralizing antibodies</term><term>Spriggs</term><term>Stott</term><term>Subgroup</term><term>Subunit</term><term>Subunit vaccine</term><term>Subunit vaccines</term><term>Surface glycoproteins</term><term>Syncytial</term><term>Syncytial virus</term><term>Vaccine</term><term>Vaccinia</term><term>Vaccinia virus</term><term>Vaccinia viruses</term><term>Virol</term><term>Virology</term><term>Virus</term><term>Virus vaccine</term><term>Wertz</term><term>Wild type virus</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Vaccines against parainfluenza (PIV) and respiratory syncytial viruses (RSV) that are currently being developed include both live and subunit vaccines. Candidate live PIV vaccines that have been found to be attenuated and efficacious in rodents or primate models are (1) cold-adapted, temperature-sensitive mutants of PIV-type 3 that have been serially passaged at low temperature (20 ° C) in simian kidney tissue culture; (2) protease-activation mutants (PIV-1-Sendai), which have mutations that decrease the cleavability of their F glycoprotein by host cell protease; (3) an animal virus, bovine PIV-3 virus, which is antigenically related to the human PIV-3 virus, and (4) vaccinia recombinant viruses bearing RSV or PIV-3 glycoproteins.Subunit RSV and PIV-3 viruses are being produced and evaluated as immunogens. A major concern with these vaccines is the possibility of disease potentiation following virus infection as occurred previously with formalin-inactivated measles and RSV vaccines. Studies indicate that PIV-3 and RSV glycoprotein vaccines are immunogenic and efficacious in animals but insufficient data exist to estimate their capacity to potentiate disease. However, since a cotton rat model is available to detect potentiated disease resulting from infection of cotton rats previously immunized with formalin-inactivated RSV vaccine, it is now possible to systematically evaluate new vaccines in experimental animals for disease potentiation before studies are initiated in humans. It is likely within the next several years that one or more of these PIV or RSV vaccines will be tested in humans for safety and immunogenicity.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R." last="Murphy">Brian R. Murphy</name></region><name sortKey="Brandt, Carl D" sort="Brandt, Carl D" uniqKey="Brandt C" first="Carl D." last="Brandt">Carl D. Brandt</name><name sortKey="Chanock, Robert M" sort="Chanock, Robert M" uniqKey="Chanock R" first="Robert M." last="Chanock">Robert M. Chanock</name><name sortKey="Collins, Peter L" sort="Collins, Peter L" uniqKey="Collins P" first="Peter L." last="Collins">Peter L. Collins</name><name sortKey="Kim, Hyun Wha" sort="Kim, Hyun Wha" uniqKey="Kim H" first="Hyun-Wha" last="Kim">Hyun-Wha Kim</name><name sortKey="Olmsted, Robert A" sort="Olmsted, Robert A" uniqKey="Olmsted R" first="Robert A." last="Olmsted">Robert A. Olmsted</name><name sortKey="Parrott, Robert H" sort="Parrott, Robert H" uniqKey="Parrott R" first="Robert H." last="Parrott">Robert H. Parrott</name><name sortKey="Prince, Gregory A" sort="Prince, Gregory A" uniqKey="Prince G" first="Gregory A." last="Prince">Gregory A. Prince</name><name sortKey="Spriggs, Melanie K" sort="Spriggs, Melanie K" uniqKey="Spriggs M" first="Melanie K." last="Spriggs">Melanie K. Spriggs</name><name sortKey="Van Wyke Coelingh, Kathleen" sort="Van Wyke Coelingh, Kathleen" uniqKey="Van Wyke Coelingh K" first="Kathleen" last="Van Wyke Coelingh">Kathleen Van Wyke Coelingh</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002222 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002222 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:392A2D76280235D3227C18F6E236015F8B932F02
|texte= Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses
}}
| This area was generated with Dilib version V0.6.33. |  |